Critical biomarkers guiding pan-cancer targeted therapy have emerged, emphasizing the importance of detecting multiple gene mutations in cancer patients for precise and effective treatment. The AmoyDx HANDLE Classic Panel encompasses 40 key solid tumor genes, enabling the detection of common mutations to support clinical therapeutic decisions with rapid turnaround time (TAT).
|
Gene
|
Alteration
|
Gene
|
Alteration
|
Gene
|
Alteration
|
Gene
|
Alteration
|
|
AKT1
|
SNV, InDel
|
FGFR1
|
SNV, InDel, Fusion
|
MAP2K1
|
SNV, InDel
|
PDGFRA
|
SNV, InDel
|
|
ALK
|
SNV, InDel, Fusion
|
FGFR2
|
SNV, InDel, Fusion
|
MET
|
SNV, InDel, Exon14 Skipping, CNA
|
PIK3CA
|
SNV, InDel
|
|
BRAF
|
SNV, InDel
|
FGFR3
|
SNV, InDel, Fusion
|
MYC
|
CNA
|
POLE
|
SNV, InDel
|
|
CDK4
|
CNA
|
FGFR4
|
SNV, InDel
|
NFE2L2
|
SNV, InDel
|
PTEN
|
SNV, InDel
|
|
CTNNB1
|
SNV, InDel
|
HRAS
|
SNV, InDel
|
NKX2-1
|
CNA
|
RB1
|
SNV, InDel
|
|
DDR2
|
SNV, InDel
|
IDH1
|
SNV, InDel
|
NRAS
|
SNV, InDel
|
RET
|
SNV, InDel, Fusion
|
|
DPYD
|
SNP
|
IDH2
|
SNV, InDel
|
NRG1
|
Fusion
|
ROS1
|
SNV, InDel, Fusion
|
|
EGFR
|
SNV, InDel
|
KEAP1
|
SNV, InDel
|
NTRK1
|
SNV, InDel, Fusion
|
STK11
|
SNV, InDel
|
|
ERBB2
|
SNV, InDel, CNA
|
KIT
|
SNV, InDel
|
NTRK2
|
SNV, InDel, Fusion
|
TP53
|
SNV, InDel
|
|
ESR1
|
SNV, InDel
|
KRAS
|
SNV, InDel
|
NTRK3
|
SNV, InDel, Fusion
|
UGT1A1
|
SNP
|
Target 40 clinically actionable genes plus MSI
Detection of SNV, Indel, fusion, CNV and MSI
Fast turnaround time within
3 days
Automatic and secure data analysis
Specifications
Sample type
FFPE
Alterations detected
SNV, InDel, Fusion, CNV, MSI
DNA input
minimum 50 ng DNA and 30 ng RNA
Publications
1. Minghao Wang, Hongtao Xu, Qiang Han & Liang Wang (2023) Significance of YAP1–MAML2 rearrangement and GTF2I mutation in the diagnosis and differential diagnosis of metaplastic thymoma, Annals of Medicine, 55:2.
2. Lu, S., Pan, H., Wu, L. et al. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Sig Transduct Target Ther 8, 249 (2023).
Inquiry